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Aim. To investigate an effect of biologically active compounds IFN-2b, EMAPII, Card medium, fibronectin on
the amount of MGMT (O
6-methylguanine-DNA methyltransferase) and MARP (anti-Methyltransferase Antibo-
dyRecognizableProtein)proteinsinhumancellsinvitro. Methods. Thehumancellsof4BL, Hep-2andA102li-
nes were treated with growth factors and cytokines. Changes in the amount of MGMT and MARP proteins were
studied by Western blot analysis with anti-MGMT mAbs. Results. The treatment of A102 cells with EMAPII, fib-
ronectin,LaferonandCardmediumledtoadecreasedleveloftheMGMTprotein,whereastheamountofMARP
was highly increased in these cells. The treatment with the recombinant protein IFN-2b increased the amount
ofMGMTandMARPproteinsinHep-2cells.Thetreatmentwithextractsoftransgenicplants,containinghuman
IFN-2b, caused a significant decrease in the content of both proteins in Hep-2 cells and MARP in 4BL cells.
Conclusions. Both MGMT and MARP are highly inducible proteins. Their amount in cells can be changed by
some growth factors (Card medium, fibronectin), cytokine (IFN-2b), cytokine-like (EMAPII) or cytokine-con-
taining substances (Laferon and IFN-2b in plant extracts). This regulation depended not only on the type of
biologically active substances but on the cell line used in this study as well.
Keywords: human cell lines, repair enzyme MGMT, MARP, cytokines, growth factors, Western blot analysis.
Introduction. The repair enzyme O
6-methylguanine-
DNA methyltransferase (MGMT) removes alkyl ad-
ducts from the O
6-position of guanine in DNA. It is the
major defense factor against the mutagenic, carcino-
genic and cytotoxic effects of alkylating agents [1, 2].
MGMT protects both normal cells from endogenous
and exogenous carcinogens and tumor cells from che-
motherapeutic alkylating compounds. Therefore, this
enzymeisconsideredtobeoneofthetargetstoregulate
antitumor efficacy of the alkylating agents [3].
According to the literature data the expression of
MGMT gene may be affected by various factors: the al-
kylating agents, single-strand DNA breaks, transcrip-
tion factors, activators of protein kinase C, the MGMT
gene promoter hypermethylation, p53 protein etc.[ 4 ,
5]. There are some works where cytokines have been
also shown to be able to influence the MGMT gene ex-
pression. For example, IFN-decreased the MGMT ge-
ne expression in human glioma and neuroblastoma cells
invitroandincreasedthesensitivityofthesecellstothe
antitumor alkylating agent temozolomide [6, 7]. IL-24
also reduced the level of the MGMT gene expression in
the human melanoma cells in dose-dependent manner
[8]. A combined action of two cytokines IL-1and IFN-
increasedthelevelofthisgeneexpressionintherat-
cells in vitro [9]. Nowadays, application of regulation
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of the MGMT gene expression with some cytokines is
launched in clinical practice. Complex treatment of the
patients, who had newly diagnosed primary glioblasto-
ma multiforme, with cytokine IFN-and temozolomide
has resulted in favorable outcome, particularly in cases
when the tumor cells contained the unmethylated MGMT
promoter [10]. So the combined action of cytokines,
which reduced the level of MGMT gene expression, and
antitumor alkylating agents improves their efficiency
in both cell lines and humans.
Theaimofourstudywastoinvestigatetheeffectof
biologicallyactivecompoundssuchasIFN-2b,EMAP
II,Cardmedium,fibronectin,ontheamountofMGMT
and MARP proteins in the human cells in vitro.
Recombinant interferon 2b (IFN-2b) is widely
used in oncology due to its well-known antitumor ac-
tivity [11]. Endothelial-monocyte activating polypep-
tide II (EMAP II), whose properties are not completely
understood, also exhibits the anticancer activity [12].
Since the MGMT gene expression is known to change
during cell differentiation [13], such factors as Card me-
dium, ATP and fibronectin, which take part in the pro-
cess of cell differentiation, were also investigated in
this study.
Biological properties of the substances mentioned
above have been known for a long time, but their pos-
sible role in regulation of the MGMT gene expression
has not been studied yet.
Materials and methods. The following human
cells were used in this study: 4BL – fibroblast-like cell
line derived in our laboratory [14], standard Hep-2 cell
line (laryngeal cancer) and A102 cell line (skin fib-
roblasts),kindlyprovidedbyProf.McCormick(Michi-
gan State University, The United States).
The cells were cultivated in standard DMEM
(«PAA», USA) with 10 % FBS («Sigma», USA) and
antibiotics penicillin (0.02 %) and streptomycin (0.02 %)
at 37
oCw i t h4%C O 2.
Different commercial and non-commercial biolo-
gically active substances were used. IFN-2b was used
as purified recombinant protein («Interpharmbiotek»,
Ukraine), in the form of commercial Laferon prepara-
tion («Interpharmbiotek») and as a component of the
crude extract of transgenic carrot plants (Daucus caro-
taL.,NantskayaandPerfektsiyavarieties).Thetransge-
niccarrotplantsexpressingIFN-2bwereobtainedvia
Agrobacterium tumefaciens-mediated transformation
using two vector constructs containing: i) the sequen-
ces encoding interferon gene fused with Nicotiana plum-
bagenifolia calreticulin apoplast targeting signal driven
by 35S CaMV promoter and selective neomycin phos-
photransferase II (nptII) gene in order to obtain the trans-
genic carrot plants able to accumulate human IFN-2b
protein; ii) the sequence encoding gusA gene driven by
35S CaMVpromoterandtheselectivenptIIgeneforob-
taining the transgenic carrot plants that we used as cont-
rolonesinourstudy–so-called«empty»vector. Accor-
ding to the previous studies the transgenic carrot plants
were characterized by high level of the recombinant hu-
man IFN-2b protein accumulation. The protein extracts
of these plants were characterized by a high antiviral
activity [15].
The purified recombinant protein EMAPII was
kindlyprovidedbyProf.A.I.Korneluk(IMBG,Ukrai-
ne).«Carddifferentiating»mediumsupplementedwith
growth factors of different origin was developed and
used in our laboratory for the differentiation of stem cells
into cardiomyocytes [16]. The commercial preparations
Fibronectin and ATP were received from «Sigma».
We used the chemical agents 5-azacytidine and mi-
tomycin C. The conditions of cell treatment with the
biologically activesubstancesintheserum-freeculture
medium were described previously [17].
Cell lysates were prepared according to [18]. SDS-
PAGE (12 % gel) was performed using Laemmli me-
thod [19]. The concentration of total protein in cell ly-
sates was measured colorimetrically according to Brad-
ford method [20].
Monoclonal anti-MGMT antibodies (clone 23.2,
isotype Ig G2b) were obtained from Novus Biologicals
(USA), secondary antibodies conjugated with horsera-
dish peroxidase were obtained from«Sigma». The pro-
cedure of MGMT identification in the samples was
performedbyWesternblotanalysisaccordingtotheme-
thodological instructions of the manufacturer of mono-
clonal antibodies (http://www.novusbio.com/ support/
protocols/protocol-specific-for-mgmt-antibody-nb100-
168.html).DensitometryofstainedmembranesbyScion-
Image 4.0.2 and Origin 8.1 programs was used as loading
control [21, 22].
Results and discussion. The human MGMT pro-
teinwasshowntohavemolecularweightof22–24kDa
KOTSARENKO K. V. ET AL.[1]. However, the Western blot analysis with mo-
noclonal anti-MGMT antibodies (clone 23.2) revealed
two highly specific immunoreactive bands – 24 kDa
(classic MGMT protein) and 48 kDa (anti-Methyl-
transferase Antibody Recognizable Protein or MARP)
(Fig. 1). It should be noted that in our previous works
MARP was named as a modified form of MGMT, whi-
le the classic 24 kDa protein was named as an unmodi-
fied form of MGMT [17, 23]. We proposed several hy-
pothesesaboutthenatureofMARP,namely,post-trans-
lation modifications, dimerization of MGMT, etc.,
which have been discussed in the mentioned articles.
So far there is an open question regarding the nature of
the 48 kDa protein.
Inthisworkwehavecomparedtheeffectofvarious
exogenous biologically active substances on the amount
of both MGMT and MARP proteins in the human cell
lines. The results of the A102 cells treatment with Card
medium, EMAPII, Laferon, fibronectin and ATP are
shown in the Fig. 2. The treatment of A102 cells with
differentexogenousfactorsledtothedramaticchanges
of the amount of MGMT and MARP proteins. Hep-2
cellswereusedaspositivecontrolinWesternblots,be-
cause they express both types of proteins (Fig. 1).
Almost all of the studied factors (except ATP) de-
creasedthelevelofMGMTproteinamountintheA102
cells (lanes 4–7) compared with the control A102 cells
(lane2).ThetreatmentwithATPandtoagreaterextent
with Card medium (lane 4), EMAP II (lane 5), Laferon
(lane 6) and fibronectin (lane 7) led to an increased
amount of MARP.
In this work we studied the influence of purified
recombinantproteinIFN-2bandtheextractoftransge-
nic carrot tissues, expressing human IFN-2b, on the
levels of MGMT and MARP proteins in Hep-2 and 4BL
cell lines.
As shown in Fig. 3, the treatment of Hep-2 cells
with the human recombinant protein IFN-2b led to
slight increase of the amount of MGMT and MARP
proteins (lanes 2 and 3). No significant changes in the
amount of MARP were detected in 4BL cells. In cont-
rast to these data, the results presented in Fig. 4 show a
significant decrease of the MGMT and MARP proteins
amount in Hep-2 cells as well as the MARP amount in
4BL cells after their treatment with the extracts of trans-
genic plant tissues, expressing human IFN-2b. On the
other hand the amount of MGMT in Hep-2 cells and
MARP in both cell lines did not significantly change
after the treatment with the extract of plants without in-
terferon gene.
We suppose that different effects of the purified re-
combinant protein IFN-2b and the interferon-con-
tainingplantextractontheMGMTandMARPproteins
amount may be caused by the influence of some plant
extract components on the action of interferon.
Thus,theresultspresentedinFig.2–4showthatthe
effect of interferon preparations may differ depending
on the composition of these preparations and the type of
celllines.Thereareseveralhypothesesaboutthemecha-
nisms of modulating the MGMT gene expression by cy-
tokines.According to oneofthemthep53 protein isin-
volved in regulation of the MGMT transcription by cy-
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Fig. 2. Effect of different biologically active substances on the amount
ofMGMTandMARPproteinsinA102cells:a–Westernblotanalysis
(1 – Hep-2, positive control; 2 – A102– control; 3 – A102 + ATP (20
g/ml);4 –A1 0 2+Ca r dm e d i u m ;5 – A102 +EMAP II(10g/ml);6 –
A102 + Laferon (20 IU/ml); 7 – A102 + fibronectin (10 g/ml)); b –
resultsofdensitometry.TheverticallinerepresentsthelevelofMGMT
and MARP proteins amount in conventional densitometry unitstokines [6, 8]. Another one suggests that the transcrip-
tionalfactorNF-Bisactivated by cytokinesand affects
the transcription of target genes including MGMT [24,
25]. We plan to continue our research of involving the-
se transcriptional factors in regulation of the MGMT gene
expressionundertheinfluenceofthestudiedcytokines.
We presume that the gene encoding MARP protein
doesnotbelongtothehousekeepinggenesbecauseitsex-
pression can be regulated by various exogenous factors.
TheHep-2cellsusually haveboth proteins(Fig.1,lane
1) as well as the 4BL cells in early passages [26]. How-
ever, after prolonged cultivation (more than 130 passa-
ges) the 4BL cells have lost the conventional MGMT
protein(Fig.1,lane2).Accordingtotheliteraturedata,
hypermethylation of the MGMT gene promoter com-
monly occurscausing agenesilencing in both different
cell lines and human cells in vivo [1, 5, 10]. Therefore
in our experiments 5-azacytidine was selected as a de-
methylating agent that can affect the MGMT gene ex-
pression in the MGMT-deficient 4BL cells (Fig. 5). 5-
azacytidinewasthefirstidentifieddemethylatingagent
thatinhibitsDNAmethyltransferasesandreversesDNA
hypermethylation, restoring the expression of silenced
genes [27]. The mechanisms involved in the 5-azacyti-
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Fig. 3. The effect of purified recombinant protein IFN-a2b on the
MGMT and MARP proteins amount in the human cell lines: a –
Western blot analysis (1 – Hep-2, control; 2 – Hep-2 + IFN-a2b (2000
IU/ml); 3 – Hep-2 + IFN-a2b (200 IU/ml); 4 – Hep-2 + IFN-a2b (2
IU/ml); 5 – 4BL, 182 p., control; 6 – 4BL + IFN-a2b (2000 IU/ml); 7 –
4BL+IFN-a2b(200IU/ml);8 –4BL+IFN-a2b(20IU/ml);9 –4BL+
IFN-a2b (2 IU/ml)); b – results of densitometry. The vertical line
represents the amount of MGMT and MARP proteins in conventional
densitometry units
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Fig. 4. The effect of extract of transgenic carrot on MGMT and MARP
proteins amount in the human cell lines: a – Western blot analysis (Hep-
2:1 –c o ntrol;2 – extract of transgenic carrot plants, containing human
IFN-a2b (600 IU/ml); 3 – extract of transgenic carrot cells transfected
with an «empty» vector; 4BL: 4 – 182 p., control; 5 – extract of trans-
genic carrot cells transfected with an «empty» vector; 6 – extract of
transgenic carrot plants, containing human IFN-a2b (600 IU/ml)); b –
results of densitometry. The vertical line represents the level of MGMT
and MARP proteins in conventional densitometry units
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Fig. 5. The effect of 5-azacytidine on the MARP protein amount in the
4BLcells(180p.):a–Westernblotanalysis(1–control;2–mitomycin
C + 5-aza (10g/ml), 8 h; 3 – 5-aza (1g/ml), 11 days; 4 – 5-aza (10
g/ml),6days;5–5-aza(10g/ml), 11days;6–mitomycinC+5-aza(1
g/ml),6 days; 7 –mitomycinC+5-aza(10g/ml),6days);b –results
of densitometry. The vertical line represents the MGMT and MARP
proteins amount in conventional densitometry unitsdine cytotoxic effects include inhibiting DNA, RNA
and protein synthesis, drug incorporation into DNA and
RNA, as well as the activation of DNA damage path-
ways. Since the non-proliferating cells are practically
insensitivetoazacytidine[28],mitomycinCwasusedin
this study as a cytostatic agent for the inhibition of cell
proliferation [29].
As shown in Fig. 5, the treatment of 4BL cells with
5-azacytidine alone or in the combination with mito-
mycin C did not influence the MGMT protein amount.
These results may indicate that the absence of the con-
ventional MGMT protein in the 4BL cells is not asso-
ciated with the promotor hypermethylation. However,
the MARP amount significantly changed under the 5-
azacytidine alone or in combination with mitomycin C
treatment. This fact requires further investigation.
Conclusions. Monoclonal anti-MGMT antibodies
(clone 23.2) recognize both the MGMT protein (M. w.
~ 24 kDa) and the unknown protein (M. w. ~ 48 kDa),
named as MARP, in Western blot analysis. These pro-
teins are highly inducible and their amount can be chan-
ged by some growth factors (Card medium, fibronec-
tin), cytokine (IFN-2b), cytokine-like (EMAP II) or
cytokine-containing substances (Laferon and IFN-2b
in plant extracts). However, this regulationdependsnot
onlyonthetypeofbiologicallyactivesubstancesbut on
the type of cell lines. The absence of MGMT protein in
4BL cells is unlikely due to the MGMT gene promotor
hypermethylation. The mechanisms of regulation of
the MGMT gene expression by growth factors and cy-
tokines require further studies.
Ê .Â .Ê î ö à ð å í ê î ,Â .Â .Ë è ë î ,Ë .Ë .Ì à ö å â è ÷ ,Ò .Ï .Ð ó á à í ,
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Âïëèâäåÿêèõá³îëîã³÷íîàêòèâíèõðå÷îâèííàâì³ñòá³ëê³âMGMT
³ MARP ó êë³òèíàõ ëþäèíè in vitro
Ðåçþìå
Ìåòà. Äîñë³äæåííÿ âïëèâó á³îëîã³÷íî àêòèâíèõ ñïîëóê IFN-2b,
EMAPII, ñåðåäîâèùà Card ³ ô³áðîíåêòèíó íà âì³ñò á³ëê³â MGMT
(Î
6-ìåòèëãóàí³í-ÄÍÊ ìåòèëòðàíñôåðàçà) ³ MARP (á³ëîê, ùî ðîç-
ï³çíàºòüñÿ àíòè-MGMT àíòèò³ëàìè) ó êë³òèíàõ ëþäèíè in vitro.
Ìåòîäè. Êë³òèíè ëþäèíè ë³í³é 4BL, Hep-2 ³ A102 îáðîáëÿëè ðîñ-
òîâèìè ôàêòîðàìè ³ öèòîê³íàìè. Çì³íè â ê³ëüêîñò³ á³ëê³â MGMT
³ MARP äîñë³äæóâàëè ç âèêîðèñòàííÿì Âåñòåðí áëîò àíàë³çó ³ ìî-
íîêëîíàëüíèõ àíòè-MGMT àíòèò³ë. Ðåçóëüòàòè. Îáðîáêà êë³-
òèí A102 ïðåïàðàòàìè EMAPII, ô³áðîíåêòèíó ³ Ëàôåðîíó ïðèçâî-
äèòü äî çíèæåííÿ ê³ëüêîñò³ á³ëêà MGMT íà ôîí³ çíà÷íîãî çðî-
ñòàííÿ ê³ëüêîñò³á³ëêà MARP ó öèõêë³òèíàõ. Îáðîáêà ðåêîìá³íàí-
òíèì á³ëêîì IFN-2b ï³äâèùóº ê³ëüê³ñòü á³ëê³â MGMT ³ MARP ó
êë³òèíàõHep-2,àåêñòðàêòàìèòðàíñãåííèõðîñëèí,ÿê³ì³ñòÿòü
IFN-2bëþäèíè,–çìåíøóºê³ëüê³ñòüîáîõá³ëê³âóêë³òèíàõHep-2
òà á³ëêàMARPóêë³òèíàõ4BL.Âèñíîâêè.MGMT³MARPºâèñîêî-
³íäóöèáåëüíèìè á³ëêàìè. ¯õíÿ ê³ëüê³ñòü ìîæå âàð³þâàòè ï³ä ä³ºþ
äåÿêèõ ðîñòîâèõ ôàêòîð³â (ñåðåäîâèùå Card ³ ô³áðîíåêòèí), öè-
òîê³íó (IFN-2b), öèòîê³íîïîä³áíîãî (EMAPII) òà öèòîê³íîâì³ñ-
íèõ (Ëàôåðîí ³ IFN-2b ó êîìïîçèö³¿ ç ðîñëèííèìè åêñòðàêòàìè)
ïðåïàðàò³â. Âèÿâëåíà ðåãóëÿö³ÿ çàëåæèòü íå ëèøå â³ä òèïó á³îëî-
ã³÷íî àêòèâíèõ ðå÷îâèí, àëå é â³ä êë³òèííèõ ë³í³é, âèêîðèñòàíèõ â
åêñïåðèìåíòàõ.
Êëþ÷îâ³ ñëîâà: ë³í³¿ êë³òèí ëþäèíè, ðåïàðàòèâíèé ôåðìåíò
MGMT, MARP, öèòîê³íè, ðîñòîâ³ ôàêòîðè, Âåñòåðí-áëîò àíàë³ç.
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Þ. Ñ. Ëó÷àêèâñêàÿ, Í. Â. Êó÷óê, Ë. Ë. Ëóêàø
Âëèÿíèå íåêîòîðûõ áèîëîãè÷åñêè àêòèâíûõ âåùåñòâ íà
ñîäåðæàíèå áåëêîâ MGMT è MARP â êëåòêàõ ÷åëîâåêà in vitro
Ðåçþìå
Öåëü. Èññëåäîâàòü âëèÿíèå áèîëîãè÷åñêè àêòèâíûõ ñîåäèíåíèé
IFN-2b, EMAP II, ñðåäû Card è ôèáðîíåêòèíà íà ñîäåðæàíèå
áåëêîâ MGMT (Î
6-ìåòèëãóàíèí-ÄÍÊ ìåòèëòðàíñôåðàçà) è
MARP(áåëîê,ðàñïîçíàâàåìûéàíòè-MGMTàíòèòåëàìè)âêëåò-
êàõ ÷åëîâåêà in vitro. Ìåòîäû. Êëåòêè ÷åëîâåêà ëèíèé 4BL, Hep-2
è A102 îáðàáàòûâàëè ðîñòîâûìè ôàêòîðàìè è öèòîêèíàìè.
Èçìåíåíèÿ â êîëè÷åñòâå áåëêîâ MGMT è MARP èññëåäîâàëè ñ èñ-
ïîëüçîâàíèåì Âåñòåðí áëîò àíàëèçà è ìîíîêëîíàëüíûõ àíòè-
MGMT àíòèòåë. Ðåçóëüòàòû. Îáðàáîòêà êëåòîêÀ102 ïðåïàðà-
òàìè EMAPII, ôèáðîíåêòèíà, Ëàôåðîíà è ñðåäû Card ñíèæàåò
êîëè÷åñòâî áåëêà MGMT íà ôîíå çíà÷èòåëüíîãî âîçðàñòàíèÿ êî-
ëè÷åñòâà áåëêà MARP â ýòèõ êëåòêàõ. Îáðàáîòêà ðåêîìáèíàíò-
í û ìá å ë ê î ìI F N - 2b óâåëè÷èâàåò êîëè÷åñòâî áåëêîâ MGMT è
MARP â êëåòêàõ Hep-2, à ýêñòðàêòàìè òðàíñãåííûõ ðàñòåíèé,
ñîäåðæàùèõ ÷åëîâå÷åñêèé IFN-2b, – ñóùåñòâåííî ñíèæàåò êî-
ëè÷åñòâî îáîèõ áåëêîâ â êëåòêàõ Hep-2 è MARP â êëåòêàõ 4BL.
Âûâîäû.MGMTèMARPÿâëÿþòñÿâûñîêîèíäóöèáåëüíûìèáåëêà-
ìè. Èõ êîëè÷åñòâî ìîæåò âàðüèðîâàòü ïîä äåéñòâèåì íåêîòî-
ðûõ ðîñòîâûõ ôàêòîðîâ (ñðåäà Card è ôèáðîíåêòèí), öèòîêèíà
(IFN-2b) öèòîêèíîïîäîáíîãî (EMAP II) è öèòîêèíñîäåðæàùèõ
(Ëàôåðîí è IFN-2b â êîìïîçèöèè ñ ðàñòèòåëüíûìè ýêñòðàêòà-
ìè)ïðåïàðàòîâ. Âûÿâëåííàÿðåãóëÿöèÿçàâèñèò íåòîëüêîîò òè-
ïàáèîëîãè÷åñêèàêòèâíûõâåùåñòâ,íîèîòêëåòî÷íûõëèíèé,èñ-
ïîëüçîâàííûõ â ýêñïåðèìåíòàõ.
Êëþ÷åâûå ñëîâà: ëèíèè êëåòîê ÷åëîâåêà, ðåïàðàòèâíûé ôåð-
ìåíò MGMT, MARP, öèòîêèíû, ðîñòîâûå ôàêòîðû, Âåñòåðí-
áëîò àíàëèç.
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